Original Study|Articles in Press

Retrospective Study to Examine Prognostic Value of C-Reactive Protein in Patients With Surgically Resectable Non-Small-Cell Lung Cancer

Published:February 06, 2023DOI:



      This study evaluated the association between elevated C-reactive protein (CRP) and clinical outcomes among adults treated with surgery for non-small cell lung cancer (NSCLC) in the US.

      Materials and Methods

      Adults with NSCLC who underwent lung cancer surgery and had ≥1 CRP measurement prior to, or >1 month following, index surgery were identified in the Optum Clinformatics claims database. The association between elevated CRP (>10 mg/L) and risk of NSCLC recurrence/death was assessed separately during the 6 months before surgery (pre surgery cohort) and 2 years following surgery (post-surgery cohort) using multivariate regressions and Kaplan-Meier analysis.


      After adjusting for baseline demographic and clinical characteristics among patients in the pre surgery cohort with index surgery between 2016 to 2020 (n = 104), the incidence rate ratio (IRR) for NSCLC recurrence between elevated vs. non-elevated CRP was 2.17 (95% confidence interval [CI]=1.03-4.60; P = .04). In the post surgery cohort (n = 264), the adjusted IRR for disease recurrence (elevated vs. non-elevated CRP) was 2.22 (95% CI=1.05-4.70; P = .04). In the pre surgery cohort, the odds of death were nearly two-fold (odds ratio [OR]=1.91; 95% CI=1.06-3.42; P = .03) among patients with elevated CRP. In the post surgery cohort, the OR was 1.62 (95% CI=0.88-2.97; P = .12). Among those with persistently elevated CRP prior to surgery, there was a significant overall trend of increased CRP over the 5-year period.


      These results support the association between elevated CRP and a higher risk of NSCLC recurrence/death in pre- and postsurgery cohorts. This study may shed lights on inflammation-suppressing treatments in patients with NSCLC.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Lung Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel RL
        • Miller KD
        • Fuchs HE
        • Jemal A.
        Cancer Statistics, 2021.
        CA Cancer J Clin. 2021; 71: 7-33
      1. American Cancer Society. What Is Lung Cancer? 2019.

        • Crvenkova S.
        Prognostic factors and survival in non-small cell lung Cancer patients treated with Chemoradiotherapy.
        Open Access Maced J Med Sci. 2015; 3: 75-79
      2. American Cancer Society. Lung Cancer survival rates 2021.

      3. American Cancer Society. Surgery for non-small cell lung Cancer 2021.

        • al-Kattan K
        • Sepsas E
        • Fountain SW
        • Townsend ER.
        Disease recurrence after resection for stage I lung cancer.
        Eur J Cardio Thorac Surg. 1997; 12: 380-384
        • Uramoto H
        • Tanaka F.
        Recurrence after surgery in patients with NSCLC.
        Transl Lung Cancer Res. 2014; 3: 242-249
        • Saisho S
        • Yasuda K
        • Maeda A
        • et al.
        Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy.
        Interact Cardiovasc Thorac Surg. 2013; 16: 166-172
        • Chaturvedi AK
        • Caporaso NE
        • Katki HA
        • et al.
        C-reactive protein and risk of lung cancer.
        J Clin Oncol. 2010; 28: 2719-2726
        • Jiang T
        • Zhou C
        • Ren S.
        Role of IL-2 in cancer immunotherapy.
        Oncoimmunology. 2016; 5e1163462
        • Silva EM
        • Mariano VS
        • Pastrez PRA
        • et al.
        High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer.
        PloS one. 2017; 12e0181125
        • Vaguliene N
        • Zemaitis M
        • Miliauskas S
        • Urboniene D
        • Sitkauskiene B
        • Sakalauskas R.
        Comparison of C-reactive protein levels in patients with lung cancer and chronic obstructive pulmonary disease.
        Medicina (Kaunas, Lithuania). 2011; 47: 421-427
        • Hara M
        • Yonei A
        • Ayabe T
        • Tomita M
        • Nakamura K
        • Onitsuka T.
        Postoperative serum C-reactive protein levels in non-small cell lung cancer patients.
        Ann Thorac Cardiovasc Surg. 2010; 16: 85-90
        • Pastorino U
        • Morelli D
        • Leuzzi G
        • et al.
        Baseline and postoperative C-reactive protein levels predict mortality in operable lung cancer.
        Eur J Cancer. 2017; 79: 90-97
        • Shinohara S
        • Otsuki R
        • Onitsuka T
        • et al.
        Postoperative C-reactive protein is a predictive biomarker for survival after non-small cell Lung Cancer Resection.
        Anticancer Re. 2019; 39: 2193-2198
        • Okada S
        • Shimomura M
        • Tsunezuka H
        • et al.
        Prognostic Significance of Perioperative C-Reactive Protein in Resected Non-Small Cell Lung Cancer.
        Semin Thorac Cardiovasc Surg. 2020; 32: 1046-1055
        • Turner RM
        • Chen YW
        • Fernandes AW.
        Validation of a Case-Finding Algorithm for Identifying Patients with Non-small Cell Lung Cancer (NSCLC) in Administrative Claims Databases.
        Front Pharmacol. 2017; 8: 883
        • Koch A
        • Fohlin H
        • Sörenson S.
        Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
        J Thorac Oncol. 2009; 4: 326-332
        • Hassett MJ
        • Uno H
        • Cronin AM
        • Carroll NM
        • Hornbrook MC
        • Ritzwoller D.
        Detecting Lung and Colorectal Cancer Recurrence Using Structured Clinical/Administrative Data to Enable Outcomes Research and Population Health Management.
        Med Care. 2017; 55: e88-e98
        • Allin KH
        • Nordestgaard BG.
        Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer.
        Crit Rev Clin Lab Sci. 2011; 48: 155-170
        • Heikkilä K
        • Silander K
        • Salomaa V
        • et al.
        C-reactive protein-associated genetic variants and cancer risk: findings from FINRISK 1992, FINRISK 1997 and Health 2000 studies.
        Eur J Cancer. 2011; 47: 404-412
        • Hart PC
        • Rajab IM
        • Alebraheem M
        • Potempa LA.
        C-Reactive Protein and Cancer-Diagnostic and Therapeutic Insights.
        Front Immunol. 2020; 11595835
        • Melosky B
        • Juergens R
        • Hirsh V
        • et al.
        Amplifying outcomes: checkpoint inhibitor combinations in first-line non-small cell lung Cancer.
        Oncologist. 2020; 25: 64-77
        • Boolell V
        • Alamgeer M
        • Watkins DN
        • Ganju V.
        The evolution of therapies in non-small cell lung cancer.
        Cancers. 2015; 7: 1815-1846
        • Zhang C
        • Leighl NB
        • Wu Y-L
        • Zhong W-Z.
        Emerging therapies for non-small cell lung cancer.
        J Hematol Oncol. 2019; 12: 45
        • Todoric J
        • Antonucci L
        • Karin M.
        Targeting Inflammation in Cancer Prevention and Therapy.
        Cancer Prev Res (Phila). 2016; 9: 895-905
        • Chakraborty A
        • Tannenbaum S
        • Rordorf C
        • et al.
        Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1beta monoclonal antibody.
        Clin Pharmacokinet. 2012; 51: e1-18
        • Ridker PM
        • MacFadyen JG
        • Thuren T
        • Everett BM
        • Libby P
        • Glynn RJ.
        Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
        Lancet (London, England). 2017; 390: 1833-1842
        • Tan D
        • Felip E
        • Castro Jr., G
        • et al.
        Canakinumab in combination with first-line (1L) pembrolizumab plus chemotherapy for advanced non‑small cell lung cancer (aNSCLC): Results from the CANOPY-1 phase 3 trial.
        in: Presented at AACR 2022; April 8-13. 2022 (Abstract CT037)